Shire PLC (LON:SHP)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank Of Canada in a note issued to investors on Friday, July 7th, Marketbeat.com reports.

Other equities analysts have also issued research reports about the company. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.82) price objective on shares of Shire PLC in a research report on Monday, April 10th. Deutsche Bank AG reissued a “buy” rating and set a GBX 6,300 ($82.27) price objective on shares of Shire PLC in a research report on Friday, April 7th. Societe Generale reissued a “buy” rating and set a GBX 6,200 ($80.96) price objective on shares of Shire PLC in a research report on Thursday, March 23rd. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Finally, Berenberg Bank reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of GBX 6,024 ($78.66).

Shares of Shire PLC (LON SHP) traded down 0.18% during mid-day trading on Friday, reaching GBX 4163.00. 1,857,246 shares of the company’s stock were exchanged. The firm’s market capitalization is GBX 37.64 billion. Shire PLC has a one year low of GBX 4,025.00 and a one year high of GBX 5,377.00. The stock has a 50-day moving average of GBX 4,348.05 and a 200 day moving average of GBX 4,589.94.

TRADEMARK VIOLATION NOTICE: “Shire PLC (SHP) Earns “Outperform” Rating from Royal Bank Of Canada” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/08/royal-bank-of-canada-reiterates-outperform-rating-for-shire-plc-shp.html.

In other Shire PLC news, insider Dominic Blakemore acquired 152 shares of Shire PLC stock in a transaction that occurred on Friday, June 30th. The stock was bought at an average cost of GBX 4,255 ($55.56) per share, for a total transaction of £6,467.60 ($8,445.55).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.